AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)

NCT01281254 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

223

Enrollment

INDUSTRY

Sponsor class

Stopped Closure of long term follow up (LTFU) and study earlier than previously outlined in the protocol as no beneficial information gained from continuing LTFU.

Conditions

Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cancer

Interventions

DRUG: AMG386 plus PLD
DRUG: Placebo plus PLD

Sponsor

Amgen